Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Feb 20;13(2):362.
doi: 10.3390/brainsci13020362.

A Comparison of the Safety, Efficacy, and Accuracy of Frame-Based versus Remebot Robot-Assisted Stereotactic Systems for Biopsy of Brainstem Tumors

Chaoxi Li  1 , Shiqiang Wu  1 , Kuan Huang  1 , Ran Li  1 , Wei Jiang  1 , Junwen Wang  1 , Kai Shu  1 , Ting Lei  1
Affiliations

A Comparison of the Safety, Efficacy, and Accuracy of Frame-Based versus Remebot Robot-Assisted Stereotactic Systems for Biopsy of Brainstem Tumors

Chaoxi Li et al. Brain Sci. .

Abstract

Background: Brainstem tumors are rare and extremely heterogeneous and present significant challenges in surgical treatment. Thus, biopsies often set the foundation for the diagnosis of brainstem tumors. Multimodal, image-guided, robot-assisted frameless stereotactic biopsies are increasingly popular in neurosurgery centers. This study aimed to compare the safety, efficacy, and duration of the Remebot robot-assisted (Remebot) frameless brainstem tumor biopsy versus those of frame-based stereotactic biopsy.

Method: A retrospective analysis of 33 patients with brainstem tumors who underwent stereotactic brainstem biopsies in the department of neurosurgery from January 2016 to January 2021 was conducted. The patients were divided into two groups: the Remebot group (n = 22) and the frame-based group (n = 11). The clinical characteristics, trajectory strategy, duration of procedure, diagnostic yielding, histopathological diagnosis, and postoperative complications were retrospectively analyzed and compared between the groups.

Results: More pediatric patients performed Remebot frameless brainstem tumor biopsy than frame-based biopsy, with a mean age of 17.3 ± 18.7 vs. 32.8 ± 17.1 (p = 0.027). The diagnostic yield had no significant difference in the two groups, with the diagnostic yield of frame-based biopsy and Remebot frameless brain biopsy being 90.9% and 95.5%, respectively. The time of the total process was 124.5 min for the frame-based biopsy and 84.7 min for the Remebot frameless brain biopsy (p < 0.001). There were no significant differences with respect to the occurrence of complication or the duration of the operation between the two groups.

Conclusion: Remebot frameless stereotactic brainstem biopsy is as safe and efficacious as frame-based stereotactic biopsy. However, Remebot frameless biopsy can reduce the total duration of the procedure and has better application in young pediatric patients. Remebot frameless stereotactic biopsies can be a better option towards the safe and efficient treatment of brainstem tumors.

Keywords: Remebot robot; biopsy; brainstem tumor; frameless; stereotactic surgery.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Image of the Remebot system.
Figure 2
Figure 2
Case presentation: (A) MRI with T1 sequence in axial view. (B) MRI T2 sequence in axial view. (C) MRI T2 flair sequence in axial view. (D) MRI T1 gadolinium sequence in axial view. (E) MRI T1 gadolinium sequence in sagittal view. (F) 1-day postoperative CT scan. (G) Surgical plan with transcerebellar approach in Remebot system.
Figure 3
Figure 3
Case presentation: (A) MRI with T1 sequence in axial view. (B) MRI T2 sequence in axial view. (C) MRI T2 flair sequence in axial view. (D) MRI T1 gadolinium sequence in axial view. (E) MRI T1 gadolinium sequence in sagittal view. (F) 1-day postoperative CT scan. (G) Surgical plan with transtemporal approach in Remebot system.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Ostrom Q.T., Price M., Ryan K., Edelson J., Neff C., Cioffi G.A., Waite K., Kruchko C., Barnholtz-Sloan J.S. CBTRUS Statistical Report: Pediatric Brain Tumor Foundation Childhood and Adolescent Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2014–2018. Neuro-Oncol. 2022;24:iii1–iii38. doi: 10.1093/neuonc/noac161. - DOI - PMC - PubMed
    1. Ostrom Q.T., Price M., Neff C., Cioffi G.A., Waite K., Kruchko C., Barnholtz-Sloan J.S. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2015–2019. Neuro-Oncol. 2022;24:v1–v95. doi: 10.1093/neuonc/noac202. - DOI - PMC - PubMed
    1. Wu S., Wang J., Gao P., Liu W., Hu F., Jiang W., Lei T., Shu K. A comparison of the efficacy, safety, and duration of frame-based and Remebot robot-assisted frameless stereotactic biopsy. Br. J. Neurosurg. 2021;35:319–323. doi: 10.1080/02688697.2020.1812519. - DOI - PubMed
    1. Wu S., Wang H., Wang J., Hu F., Jiang W., Lei T., Shu K. Effect of Robot-Assisted Neuroendoscopic Hematoma Evacuation Combined Intracranial Pressure Monitoring for the Treatment of Hypertensive Intracerebral Hemorrhage. Front. Neurol. 2021;12:722924. doi: 10.3389/fneur.2021.722924. - DOI - PMC - PubMed
    1. Louis D.N., Perry A., Wesseling P., Brat D.J., Cree I.A., Figarella-Branger D., Hawkins C., Ng H.K., Pfister S.M., Reifenberger G., et al. The 2021 WHO Classification of Tumors of the Central Nervous System: A summary. Neuro-Oncol. 2021;23:1231–1251. doi: 10.1093/neuonc/noab106. - DOI - PMC - PubMed

LinkOut - more resources